India approves first dengue vaccine for individuals aged 4 to 60 years
India has approved Takeda’s QDENGA, the country's first dengue vaccine, for individuals aged 4 to 60. The vaccine, which protects against all four dengue serotypes, has shown high efficacy in preventing hospitalizations in long-term clinical trials.
Why it matters
Dengue is a major public health burden in India; the introduction of a vaccine could significantly reduce morbidity and the strain on the healthcare system.
The Drug Controller General of India (DCGI) has granted market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK-003), making it the first dengue vaccine to be approved in the country, according to a press release issued by the company.
The vaccine has been approved for the prevention of dengue disease in individuals aged 4 to 60 years. QDENGA is a live-attenuated tetravalent vaccine designed to provide protection against all four dengue virus serotypes and is administered as a two-dose regimen, with doses given three months apart.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in